Jason V. Coloma
CIK: 0001676170
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (29 total)
- Oct 1, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect31.9K shares at avg. $27.02$862K - Oct 1, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect2.6K shares at avg. $27.02$70K - Sep 3, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct129 shares at avg. $25.77$3K - Sep 3, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct11.3K shares at avg. $26.01$293K - Sep 2, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct9.9K shares at avg. $26.38$260K - Sep 2, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct1.4K shares at avg. $27.12$37K - Sep 1, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect31.9K shares at avg. $26.29$839K - Sep 1, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect2.6K shares at avg. $26.31$68K - Sep 1, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct50K shares- - Aug 3, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect2.4K shares at avg. $26.71$65K - Aug 3, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect1.6K shares at avg. $27.09$43K - Aug 3, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect30.3K shares at avg. $26.71$810K - Aug 3, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect154 shares at avg. $27.09$4K - Jul 1, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect30.3K shares at avg. $29.95$908K - Jul 1, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect1.6K shares at avg. $30.44$49K - Jul 1, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect2.6K shares at avg. $29.98$78K - Jun 23, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect23.9K shares at avg. $26.05$622K - Jun 22, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect2K shares at avg. $26.00$51K - Jun 22, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect2K shares at avg. $26.00$53K - Jun 1, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect6.1K shares at avg. $26.20$160K - Jun 1, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect553 shares at avg. $26.24$15K - May 26, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect25.6K shares at avg. $26.02$666K - May 22, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect2.5K shares at avg. $26.00$64K - May 22, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect4.5K shares at avg. $26.00$117K - May 15, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Indirect1.8K shares at avg. $26.00$47K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 1, 2026 |  MAZE Maze Therapeutics, Inc. | Sale(S) | 31,908 | $27.02 | $862,186 | Indirect |
| Oct 1, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 2,593 | $27.02 | $70,073 | Indirect |
| Sep 3, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 129 | $25.77 | $3,325 | Direct |
| Sep 3, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 11,282 | $26.01 | $293,482 | Direct |
| Sep 2, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 9,852 | $26.38 | $259,856 | Direct |
| Sep 2, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 1,375 | $27.12 | $37,292 | Direct |
| Sep 1, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 31,908 | $26.29 | $838,785 | Indirect |
| Sep 1, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 2,593 | $26.31 | $68,214 | Indirect |
| Sep 1, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 50,000 | - | $0 | Direct |
| Aug 3, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 2,439 | $26.71 | $65,157 | Indirect |
| Aug 3, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 1,604 | $27.09 | $43,445 | Indirect |
| Aug 3, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 30,304 | $26.71 | $809,541 | Indirect |
| Aug 3, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 154 | $27.09 | $4,172 | Indirect |
| Jul 1, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 30,311 | $29.95 | $907,921 | Indirect |
| Jul 1, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 1,597 | $30.44 | $48,606 | Indirect |
| Jul 1, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 2,593 | $29.98 | $77,726 | Indirect |
| Jun 23, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 23,865 | $26.05 | $621,674 | Indirect |
| Jun 22, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 1,953 | $26.00 | $50,781 | Indirect |
| Jun 22, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 2,040 | $26.00 | $53,040 | Indirect |
| Jun 1, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 6,090 | $26.20 | $159,537 | Indirect |
| Jun 1, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 553 | $26.24 | $14,511 | Indirect |
| May 26, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 25,582 | $26.02 | $665,516 | Indirect |
| May 22, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 2,478 | $26.00 | $64,428 | Indirect |
| May 22, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 4,504 | $26.00 | $117,104 | Indirect |
| May 15, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 1,822 | $26.00 | $47,372 | Indirect |
1-25 of 29 transactions
About Coloma Jason V
Coloma Jason V (SEC CIK 0001676170) files insider reports with the SEC as Chief Executive Officer of Maze Therapeutics, Inc. (MAZE) and Director of Braveheart Bio, Inc. (BRVE).
Signal8 holds 13 ownership filings by Coloma Jason V (2 Form 3, 11 Form 4), filed between Jan 30, 2025 and Oct 2, 2026. Those filings report 29 transactions, from Sep 22, 2025 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Coloma Jason V's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Coloma Jason V
- Oct 1, 2026: Open-market sales of MAZE shares (2 lines, Form 4, code S).
- Sep 3, 2026: Open-market sales of MAZE shares (2 lines, Form 4, code S).
- Sep 2, 2026: Open-market sales of MAZE shares (2 lines, Form 4, code S).
- Sep 1, 2026: Open-market sales of MAZE shares (2 lines, Form 4, code S).
- Sep 1, 2026: Option exercise of MAZE shares (Form 4, code M).
Other insiders filing for Maze Therapeutics, Inc. (MAZE)
- Dandekar Atul, CSBO
- Bernstein Harold, President, R&D & CMO
- Courtney Phillips, GC and Corp. Secretary
- Kornowski Sophie, Director
- Johnson Paula A, Director
- SPIEGELMAN DANIEL K, Director